NEW YORK (Thomson Financial) - Hollis-Eden Pharmaceuticals Inc. Thursday
said its drug Triolex has been chosen by the Cystic Fibrosis Foundation
Therapeutics as a drug candidate for lung inflammation associated with cystic
fibrosis.
Hollis-Eden, a San Diego-based pharmaceutical company, has an existing
collaboration agreement with the nonprofit group.
The company said it expects to receive milestone payments of $645,000 from
the group upon the achievement of certain development milestones.
Shares of Hollis-Eden closed Wednesday at $1.73.
Ryan Vlastelica
rv/jw
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|